United States Self-Monitoring Blood Glucose Market Size and Share
Market Overview
| Study Period | 2021 - 2032 |
|---|---|
| Forecast Data Period | 2027 - 2032 |
| Historical Data Period | 2021 - 2025 |
| Base Year Market Size (2026) | USD 8.63 Billion |
| Market Size (2027) | USD 9.18 Billion |
| Market Size (2032) | USD 12.53 Billion |
| Growth Rate (2027 - 2032) | 6.41 % |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
United States Self-Monitoring Blood Glucose Market Analysis by Mordor Intelligence
The United States Self-Monitoring Blood Glucose Market size was valued at USD 8.63 billion in 2026 and is estimated to grow from USD 9.18 billion in 2027 to reach USD 12.53 billion by 2032, at a CAGR of 6.41% during the forecast period (2027-2032).
According to the CDC, routine diabetes management was important to reduce the risk of bad health outcomes and severe COVID-19 in diabetes patients. However, the pandemic caused disruptions in diabetes management, a worsening of glycemic control, and more cases of severe diabetic ketoacidosis. Between April and August 2020, about 60% of people who were just diagnosed with type 1 diabetes had diabetic ketoacidosis as their first sign or symptom.This is about twice as many as in previous years, which suggests that people with diabetes are taking longer to seek care and get diagnosed. During the COVID-19 pandemic, glycemic control got better when people used telemedicine or checked their own blood sugar.
In the United States Self-Monitoring Blood Glucose Market, blood glucose monitoring increases patients’ awareness of their glucose levels, supporting healthier lifestyle choices and informed diabetes management. Self-monitoring blood glucose devices provide feedback and guidance on necessary health behavior changes, including dietary adjustments, physical activity, and medication adherence. Persistent elevation of blood glucose levels among patients with diabetes can lead to progressive complications, including renal, neurological, and ocular damage. Appropriate and timely self-monitoring of blood glucose enables the effective management of out-of-range glucose levels, thereby minimizing diabetes-related health complications. The rising burden of diabetes and the increasing emphasis on self-management and preventive care continue to support demand for self-monitoring blood glucose devices and testing supplies in the United States.
According to the National Center for Health Statistics, approximately 32.8% of adults aged 18 and over in the United States will be obese in 2021. When a person is overweight, their fat cells release chemicals that cause inflammation. These chemicals may make the body less sensitive to the insulin it makes by messing up the way insulin-responsive cells work. So, these people need insulin shots from the outside and have to use a device like a glucometer to check their blood sugar.
Innovative technologies, such as digital health applications that display and summarize individual blood glucose readings alongside relevant data, including insulin doses, meals or snacks, and physical activity, can help people manage diabetes more effectively. These technologies can reduce the burden of the disease and improve overall care. The integration of self-monitoring blood glucose devices with insulin calculators, automated insulin titration software, and remote coaching represents a key development in the United States market. These solutions provide additional support to patients with poorly controlled diabetes, helping improve critical health outcomes. Furthermore, the availability of connected glucose meters and mobile applications enables healthcare providers to remotely monitor patient data and offer timely interventions. Such technological advancements are expected to support the growth prospects of the United States Self-Monitoring Blood Glucose Market over the coming years.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
United States Self-Monitoring Blood Glucose Market Trends and Insights
Rising Diabetes Prevalence in the United States
According to the CDC's National Diabetes Statistics Report 2022, more than 130 million adults in the United States have diabetes or prediabetes. People of color, people who live in rural areas, and people with less education, lower incomes, and less health literacy are more likely to have type 2 diabetes, and it is more dangerous for them.
The ADA, the Endocrine Society, the American College of Physicians, the American Academy of Pediatrics, the Society of General Internal Medicine, and the National Academy of Medicine all put out statements and calls to action about SDOH at the individual, organizational, and policy levels.In 2021, the ADA also published a scientific review about the links between SDOH and diabetes risk and outcomes. The review focused on socioeconomic status, health literacy, the food environment, food insecurity, and the neighborhood and physical environments, among other things.
In the United States, there are several innovations in diabetes management platforms by startups, like Glooko, OneDrop, Verily, Vacate, Insulet, Noom, Bigfoot Biomedical, Virta Health, Diabeloop, and Orgenesis, which have launched in the market. People are learning more about advanced diabetes devices, which is making blood glucose monitoring devices more flexible.To get a large share of the market, the top manufacturers are putting a lot of effort into developing new technologies and making more advanced products.
In May 2021, the World Health Assembly agreed on a resolution to make it easier to stop diabetes and keep it under control.It makes suggestions for things that can be done, like making insulin easier to get and making sure that insulin and other medicines and health products used to treat diabetes have the same rules.In May 2022, the World Health Assembly agreed on five goals for the treatment and coverage of diabetes around the world by 2030.
Therefore, the studied market is anticipated to witness growth over the analysis period due to rising prevalence and the aforementioned factors.
The Test Strips Segment held the highest market share in the current year
The Test Strips Segment recorded a market share of about 80% in the current year.
Blood glucose test strips are small, disposable strips that are a key component of blood glucose testing. When blood is placed on the test strip, it reacts with a chemical called glucose oxidase, producing gluconic acid from the glucose in the blood. At the other end of the test strip, the meter transfers a current to the test strip. The test strip has electric terminals, which allow the meter to measure the current between the terminals. The current between the terminals changes depending on the level of gluconic acid that has been produced. The blood glucose meter then uses an algorithm to work out the blood glucose level based on the difference in current.
The growth in market share of test strips is expected to be higher than that of glucose meters because of the difference in use-case frequency. The glucometer is a one-time purchase; however, test strips, on the other hand, are a continuous investment as a test strip needs to be disposed of after one use, causing a recurrent cost impact. An average glucose meter lasts anywhere between six months and three years, presenting a one-time cost during the same time frame.
The federal health insurance program Medicare (Part B and Part D) pays for diabetes supplies to help doctors, providers, suppliers, and other healthcare professionals who give diabetic supplies to people with Medicare. Medicare Part B covers diabetic supplies such as blood glucose self-testing equipment and supplies, therapeutic shoes and inserts, insulin pumps, and the insulin used in the pumps. Blood glucose self-testing equipment and supplies are covered for all people with Medicare Part B who have diabetes. This includes those who use insulin and those who do not use insulin. Such reimbursement policies and the aforementioned factors are expected to drive the market over the forecast period.
Competitive Landscape
The United States self-monitoring blood glucose market is moderately fragmented, with a few significant and other generic players. Manufacturers like i-Sens, Abbott, LifeScan, and Ascensia occupy a major share.
United States Self-Monitoring Blood Glucose Industry Leaders
-
Abbott Diabetes Care
-
Ascensia Diabetes Care
-
Roche Diabetes Care
-
Arkray Inc.
-
LifeScan Inc.
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes-one of the largest combined blood glucose meter and mobile diabetes app datasets ever published.
- 2022: Roche announced the launch of the COBAS pulse system in selected countries accepting the CE mark. The COBAS pulse system marks Roche Diagnostics' newest generation of connected point-of-care solutions for professional blood glucose management. The COBAS pulse system combines the form factor of a high-performance blood glucose meter with simple usability and expanded digital capabilities like those of a smartphone. Following first commercial availability under the CE mark in select markets, Roche plans to seek CE IVDR and FDA clearance for the Cobas Pulse System in other global markets.
United States Self-Monitoring Blood Glucose Market Report Scope
Diabetic patients can measure their own blood sugar levels using a glucometer, test strips, and lancets by self-monitoring their blood glucose.Based on the readings, patients can adjust or check the effect of their treatment. The United States self-monitoring blood glucose market is segmented into components (glucometer devices, test strips, and lancets). The report offers the value (in USD million) and volume (in million units) for the above segments.
| Glucometer Devices |
| Test Strips |
| Lancets |
| Component (Value and Volume, 2017 - 2028) | Glucometer Devices |
| Test Strips | |
| Lancets |
Key Questions Answered in the Report
How big is the United States Self-Monitoring Blood Glucose Market?
The United States Self-Monitoring Blood Glucose Market size is expected to reach USD 9.18 billion in 2027 and grow at a CAGR of 6.41% to reach USD 12.53 billion by 2032.
What is the current United States Self-Monitoring Blood Glucose Market size?
In 2026, the United States Self-Monitoring Blood Glucose Market size is expected to reach USD 8.63 billion.
Who are the key players in United States Self-Monitoring Blood Glucose Market?
Abbott Diabetes Care, Ascensia Diabetes Care, Roche Diabetes Care, Arkray Inc. and LifeScan Inc. are the major companies operating in the United States Self-Monitoring Blood Glucose Market.
What years does this United States Self-Monitoring Blood Glucose Market cover, and what was the market size in 2025?
In 2025, the United States Self-Monitoring Blood Glucose Market size was estimated at USD 8.11 billion. The report covers the United States Self-Monitoring Blood Glucose Market historical market size for years: 2021, 2022, 2023, 2024, and 2025. The report also forecasts the United States Self-Monitoring Blood Glucose Market size for years: 2027, 2028, 2029, 2030, 2031, and 2032.